[Change in the Proton Pump Inhibitors (PPI) terms for coverage: a follow-up]
Régie de l'assurance maladie du Québec, Jehanno C, Baril J, Chamberland C
Record ID 32014001081
French
Authors' recommendations:
Since October 1, 2013, following the implementation of an Institut national d'excellence en santé et en services sociaux (INESSS) recommendation, the total cost of reimbursing proton pump inhibitors (PPIs) has decreased significantly for the public prescription drug insurance plan, from a monthly average of $16.5 million in January 2012 to $8.9 million in March 2014. This is according to Suivi de la mesure de remboursement des inhibiteurs de la pompe à protons (IPP), a follow-up report to the March 2013 public notice, which recommended to the Minister that he give preference to scenarios for reimbursing three or four generic PPIs based on the application of a measure referred to as the maximum payable price (MPP).
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.inesss.qc.ca/fileadmin/doc/INESSS/Rapports/Medicaments/INESSS_Suivi_de_la_mesure_de_remboursement_des_IPP.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Proton Pump Inhibitors
- Health Benefit Plans, Employee
- Drug Costs
Contact
Organisation Name:
Institut national d'excellence en sante et en services sociaux
Contact Address:
L'Institut national d'excellence en sante et en services sociaux (INESSS) , 2021, avenue Union, bureau 10.083, Montreal, Quebec, Canada, H3A 2S9;Tel: 1+514-873-2563, Fax: 1+514-873-1369
Contact Name:
demande@inesss.qc.ca
Contact Email:
demande@inesss.qc.ca
Copyright:
©Gouvernement du Québec/Institut national d'excellence en santé et en services sociaux
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.